Thalidomide Capsules
» Thalidomide Capsules contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of thalidomide (C13H10N2O4).
Packaging and storage— Preserve in tight containers, protected from light, at controlled room temperature. Do not repackage.
USP Reference standards 11
USP Thalidomide RS Click to View Structure
Identification—
A: Thin-Layer Chromatographic Identification Test 201
Test solution— Prepare a solution of it in acetonitrile containing about 3000 µg of thalidomide per mL.
Application volume: 5 µL.
Developing solvent system: a mixture of normal butyl acetate, glacial acetic acid, and butyl alcohol (50:25:5).
B: The relative retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Microbial enumeration tests 61 and Tests for specified microorganisms 62 The total aerobic microbial count using the Plate Method is not more than 1000 cfu per g, and the total combined molds and yeasts count is not more than 100 cfu per g. It meets the requirements of the test for absence of Escherichia coli.
Dissolution 711
Medium— Add 1.0 mL of polyoxyethylene (23) lauryl ether solution, prepared by dissolving 50 g in 100 mL of water, to 0.225 M hydrochloric acid; 4000 mL.
Apparatus 2: 75 rpm.
Time: 60 minutes.
Determine the amount of C13H10N2O4 dissolved by employing the following method.
Mobile phase— Prepare as directed in the Assay under Thalidomide.
Internal standard solution— Prepare a solution of phenacetin in acetonitrile containing about 375 µg per mL. Pipet 20.0 mL of this solution into a 100-mL volumetric flask, add 10.0 mL of phosphoric acid solution (1 in 100), dilute with water to volume, and mix.
Standard solution— Dissolve an accurately weighed quantity of USP Thalidomide RS in acetonitrile to obtain a solution having a known concentration of about 0.25 mg per mL. Pipet 10.0 mL of this solution into a 100-mL volumetric flask, add 10.0 mL of phosphoric acid solution (1 in 100), dilute with water to volume, and mix. Add 5.0 mL of Internal standard solution to 20.0 mL of this solution, and mix. This solution contains about 0.02 mg of USP Thalidomide RS per mL.
Test solution— Add 5.0 mL of Internal standard solution to each 20.0 mL of filtered solution under test, and mix.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of C13H10N2O4 dissolved by the formula:
2500C(RU / RS)
in which C is the concentration, in mg per mL, of USP Thalidomide RS in the Standard solution; and RU and RS are the peak area ratios of thalidomide to the internal standard obtained from the Test solution and the Standard solution, respectively.
Tolerances— Not less than 70% (Q) of the labeled amount of C13H10N2O4 is dissolved in 60 minutes.
Uniformity of dosage units 905: meet the requirements.
Assay—
Mobile phase, Internal standard preparation, Standard preparation, and Chromatographic system— Prepare as directed in the Assay under Thalidomide.
Assay preparation— Remove, as completely as possible, the contents of not fewer than 20 Capsules, and weigh accurately. Mix the combined contents, and transfer an accurately weighed portion of the powder, equivalent to about 50 mg of thalidomide, to a 100-mL volumetric flask, add 80 mL of acetonitrile to dissolve, and sonicate for about 20 minutes. Dilute with acetonitrile to volume, and mix. Transfer 20.0 mL of this solution and 5.0 mL of Internal standard preparation to a 100-mL volumetric flask, add 10.0 mL of phosphoric acid solution (1 in 100), dilute with water to volume, and mix.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of thalidomide (C13H10N2O4) in the portion of Capsules taken by the formula:
1000C(RU / RS)
in which C is the concentration, in mg per mL, of USP Thalidomide RS in the Standard preparation; and RU and RS are the peak area ratios of thalidomide to the internal standard obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Feiwen Mao, M.S.
Senior Scientific Liaison
1-301-816-8320
(SM32010) Monographs - Small Molecules 3
Reference Standards RS Technical Services
1-301-816-8129
rstech@usp.org
61 Radhakrishna S Tirumalai, Ph.D.
Principal Scientific Liaison
1-301-816-8339
(GCM2010) General Chapters - Microbiology
62 Radhakrishna S Tirumalai, Ph.D.
Principal Scientific Liaison
1-301-816-8339
(GCM2010) General Chapters - Microbiology
711 Margareth R.C. Marques, Ph.D.
Senior Scientific Liaison
1-301-816-8106
(GCDF2010) General Chapters - Dosage Forms
USP35–NF30 Page 4821
Pharmacopeial Forum: Volume No. 32(5) Page 1468